Description
Recombinant Human T-cell Immunoreceptor Protein
| Catalog number: | B2012929 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 10 uL |
| Molecular Weight or Concentration: | 26.3 kDa |
| Supplied as: | Lyophilized Powder |
| Applications: | molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Recombinant protein |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Beck JD, Reidenbach D, Salomon N, Sahin U, Treci , Vormehr M, Kranz LM. mRNA therapeutics in cancer immunotherapy Mol Cancer. 2021 Apr 15;20(1):69.
- Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, Milone MC, Payne AS. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease Science. 2016 Jul 8;353(6295):179-84.
- Bonnefoy N, Olive D, Vanhove B. [Next generation of anti-immune checkpoints antibodies] Med Sci (Paris). 2019 Dec;35(12):966-974.
- Saito M, Suzuki H, Kaneko MK, Kato Y. TgMab-2: An Anti-human T Cell Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Motif Domain Monoclonal Antibody for Immunocytochemistry Monoclon Antib Immunodiagn Immunother. 2022 Jun;41(3):157-162.
- Hombach A, Heuser C, Abken H. The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy Curr Gene Ther. 2002 May;2(2):211-26.
- Kawalekar O, June CH, Milone MC. Studying Immunoreceptor Signaling in Human T Cells Using Electroporation of In Vitro Transcribed mRNA Methods Mol Biol. 2017;1584:443-450.
- Zhang H, Zhang Y, Dong J, Zuo S, Meng G, Wu J, Wei J. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8(+) T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma Cell Oncol (Dordr). 2021 Dec;44(6):1243-1255.
- Hombach A, Schlimper C, Sievers E, Frank S, Schild HH, Sauerbruch T, Schmidt-Wolf IG, Abken H. A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells Gut. 2006 Aug;55(8):1156-64.
- Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abken H. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule J Immunol. 2001 Dec 1;167(11):6123-31.
